Secondary Hyperparathyroidism

If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Email*

Password*

Keep me logged in Forgot your password?

Email*

High, Low PTH Raises Hypercalcemia Risk

Jody A. Charnow May 13, 2012

NATIONAL HARBOR, Md.—Low and high levels of parathyroid hormone (PTH) are associated with hypercalcemia, according to a study of 106,760 hemodialysis patients presented at the National Kidney Foundation 2012 Spring Clinical Meetings suggest.

Novel Formulation Corrects Vitamin D, Lowers iPTH

Jody A. Charnow May 13, 2012

NATIONAL HARBOR, Md.—An investigational treatment safely and effectively lowers elevated plasma intact parathyroid hormone (iPTH) levels in patients with stage 3 or 4 chronic kidney disease and vitamin D deficiency, researchers reported at the National Kidney Foundation 2012 Spring Clinical Meetings.

SHPT Linked to Vitamin D Deficiency in CKD Patients

Jody A. Charnow May 12, 2012

NATIONAL HARBOR, Md.—Vitamin D deficiency is strongly associated with secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), according to data presented at the National Kidney Foundation (NKF) 2012 Spring Clinical Meetings.

Labs May Vary in iPTH Measurements

Jody A. Charnow May 12, 2012

NATIONAL HARBOR, Md.—Laboratories can differ in their measurements of intact parathyroid hormone (iPTH) levels, resulting in varying treatment approaches for hemodialysis (HD) patients depending on the iPTH assay used, researchers reported at the National Kidney Foundation Spring Clinical Meetings.

CKD Patients May Need Higher 25D Levels

Jody A. Charnow May 11, 2012

NATIONAL HARBOR, Md.—Levels of 25-hydroxyvitamin D (25D) higher than 20 ng/mL would be required to normalize intact parathyroid hormone (iPTH) in patients with stages 3 and 4 chronic kidney disease (CKD) with vitamin D insufficiency and secondary hyperparathyroidism, researchers concluded in a study presented at the National Kidney Foundation 2012 Spring Clinical Meetings.

Calcitriol as Effective as Vitamin D Analogues, but Cheaper

Jody A. Charnow May 11, 2012

NATIONAL HARBOR, Md.—Oral calcitriol is as effective as vitamin D analogues for treating secondary hyperparathyroidism (SHPT) in hemodialysis patients but is more cost effective, according to a study presented at the National Kidney Foundation 2012 Spring Clinical Meetings.

Calcifediol May Improve PTH Control, Nutritional Status

Jody A. Charnow November 12, 2011

PHILADELPHIA—Adequate doses of calcifediol can correct 25-hydroxyvitamin D deficiency and improve malnutrition-inflammation status in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT), researchers reported at Kidney Week 2011.

Cinacalcet Plus Low-Dose Vitamin D Improves SHPT Treatment

Jody A. Charnow November 12, 2011

PHILADELPHIA—Cinacalcet plus low-dose vitamin D provides a more effective approach to treating secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients, according to findings presented at Kidney Week 2011.

Uncontrolled SHPT On the Rise in Blacks Since Debut of 'Bundling'

Jody A. Charnow November 12, 2011

PHILADELPHIA—Uncontrolled secondary hyperparathyroidism (SHPT) has been on the increase among black hemodialysis (HD) patients since the recent implementation of the federal government's prospective payment system for dialysis services, researchers reported at Kidney Week 2011.

Untreated SHPT Increases Mortality Risk

Jody A. Charnow November 11, 2011

PHILADELPHIA—Untreated secondary hyperparathyroidism (SHPT) is associated with increased mortality risk in hemodialysis (HD) patients, according to a report presented at Kidney Week 2011.

Treating SHPT with Cinacalcet Lowers Phosphorus

Jody A. Charnow November 11, 2011

PHILADELPHIA—Serum phosphorus levels in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) decrease during treatment with cinacalcet, data presented at Kidney Week 2011 show. This effect occurs regardless of baseline SHPT severity.

Two Vitamin D Analogues Show Similar Efficacy for SHPT

Jody A. Charnow November 11, 2011

PHILADELPHIA—Alfacalcidol and paricalcitol have similar efficacy in suppressing secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients researchers reported at Kidney Week 2011.

Vitamin D Regimen May Treat SHPT in Renal Transplant Patients

Jody A. Charnow November 10, 2011

PHILADELPHIA—Cholecalciferol with or without doxercalciferol may be an appropriate treatment for secondary hyperparathyroidism (SHPT) in kidney transplant recipients, according to the findings of a small study presented at Kidney Week 2011.

High PTH and FGF-23 Predict Vascular Calcification

Jody A. Charnow November 10, 2011

PHILADELPHIA—Elevated levels of serum parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23) are associated with an increased likelihood of progression of vascular calcification (VC) in hemodialysis patients, French researchers reported at Kidney Week 2011.

Study Identifies Predictors of Cinacalcet Use After Transplantation

Jody A. Charnow November 10, 2011

PHILADELPHIA—The dose of cinacalcet dialysis patients receive prior to renal transplantation and their time on dialysis appear to be the most important factors associated with reintroduction of the drug during the first year following transplantation, Spanish researchers reported at Kidney Week 2011.

Paricalcitol Superior for Lowering iPTH

Daniel M. Keller, PhD July 18, 2011

The drug was more likely than cinacalcet to achieve a 50 percent or greater decrease in iPTH from baseline.

Antioxidant Nutraceutical May Help Treat Secondary Hyperparathyroidism

Jody A. Charnow April 30, 2011

LAS VEGAS—A novel multivitamin antioxidant nutraceutical may be useful in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients, according to data reported at the National Kidney Foundation's Spring Clinical Meetings.

Inpatient Savings May Offset Cinacalcet Costs

Jody A. Charnow April 29, 2011

LAS VEGAS—Inpatient cost savings may offset the costs of patient adherence to cinacalcet therapy, according to study findings presented at the National Kidney Foundation's Spring Clinical Meetings.

Paricalcitol Found Better for Lowering PTH

Jody A. Charnow April 09, 2011

VANCOUVER, B.C.—Paricalcitol is more effective than ergocalciferol at lowering parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD) stages 3 and 4 and who have vitamin D deficiency and secondary hyperparathyroidism, data suggest.

Cinacalcet May Reduce ESA Use

Jody A. Charnow February 23, 2011

PHOENIX—Cinacalcet hydrochloride (CH) treatment in dialysis patients with secondary hyperparathyroidism may improve responsiveness to an erythropoiesis-stimulating agent (ESA) by reducing systemic inflammation, resulting in decreased ESA requirements, new data suggest.

Our exclusive coverage of Kidney Week 2011 in Philadelphia includes interviews, videos and noteworthy clinical reports.

Sections: Anemia | Transplantation
Secondary Hyperparathyroidism | General News
More: Videos

On The Forefront

Sickle Cell Trait and Medullary Renal Carcinoma

A 55-year-old Caucasian woman initially presented to one of Cleveland Clinic's regional outpatient urology clinics with gross hematuria and an obstructing right ureteral stone.

Current Poll

Has a radiologist ever challenged one of your orders for an imaging procedure?

Click here to take the poll

Commentary

Prostate Cancer Screening: Moving Beyond PSA

The merits of PSA screening have been widely debated due largely to its low specificity for prostate cancer (PCa), especially for high-grade disease.

Cartoons

Click here for our latest cartoons

Expert Q&A

Optimal Sequencing of the New Prostate Cancer Drugs: An Interview with E. David Crawford, MD

Several new drugs have become available for treating advanced prostate cancer in the past year and a half. Dr. Crawford talks to Renal & Urology News about the possible ways in which these drugs might be used.